Shares of Dechra Pharmaceuticals plc (LON:DPH) have been given a consensus rating of “Buy” by the eight brokerages that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is GBX 1,784 ($24.01).

Separately, Jefferies Group upped their target price on shares of Dechra Pharmaceuticals from GBX 1,565 ($21.06) to GBX 1,868 ($25.14) and gave the company a “hold” rating in a report on Tuesday, September 5th.

Shares of Dechra Pharmaceuticals (DPH) traded down GBX 24 ($0.32) during trading hours on Thursday, hitting GBX 2,046 ($27.54). 174,060 shares of the stock were exchanged, compared to its average volume of 134,527. Dechra Pharmaceuticals has a 1-year low of GBX 1,225 ($16.49) and a 1-year high of GBX 2,272 ($30.58).

In related news, insider Ian Page sold 54,910 shares of the stock in a transaction dated Tuesday, September 19th. The shares were sold at an average price of GBX 2,024 ($27.24), for a total transaction of £1,111,378.40 ($1,495,798.65).

ILLEGAL ACTIVITY NOTICE: “Dechra Pharmaceuticals plc (DPH) Given Consensus Recommendation of “Buy” by Brokerages” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at

Dechra Pharmaceuticals Company Profile

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.

Analyst Recommendations for Dechra Pharmaceuticals (LON:DPH)

Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with's FREE daily email newsletter.